Viasonix

Viasonix operates in medical devices and health diagnostics, with a specific emphasis on vascular and neurovascular assessment. Its product range brings together peripheral physiologic testing through the Falcon line and cerebral blood-flow assessment through the Dolphin transcranial Doppler line. That breadth distinguishes its stated offering from a portfolio focused only on one type of vascular examination, while configurable protocols, reporting functions, and DICOM, HL7, EMR, and PACS connectivity address clinical workflow needs. The company’s materials describe its systems as upgrade options for older-generation Nicolet Vasoguard and Sonara systems; those are legacy products cited for comparison, not verified current competitors. Viasonix is classified as a private company with an employee range of 11–50. Its differentiation is therefore best assessed through its combined diagnostic scope, portability and monitoring options, robotic probe technology, and healthcare-system integration rather than through unsupported claims about market share or relative scale.

Viasonix was founded in 2009 and remains listed as active, with its headquarters in Ra'anana, Israel. Its development trajectory, as reflected in the available details, centers on extending a vascular diagnostic portfolio rather than on a documented sequence of financing or acquisitions. The company’s 2021 announcement of an FDA-cleared robotic probe for bilateral brain-flow scanning and a 2022 patent publication relating to transcranial Doppler technology mark identifiable milestones in its neurovascular work. Its current product descriptions cover both Falcon peripheral vascular assessment and Dolphin cerebral-flow systems, including portable and monitoring configurations. Website information also describes connectivity and reporting features intended for clinical and research workflows. The evidence supports a product- and technology-led history, while leaving commercial scale, sales growth, and the pace of development after the documented milestones uncertain.